12-20_0331_Number of shares and voting rights in Zealand Pharma at March 31
Kurs & Likviditet
Beskrivning
| Land | Danmark |
|---|---|
| Lista | Mid Cap Copenhagen |
| Sektor | Hälsovård |
| Industri | Bioteknik |
Company announcement – No. 12 / 2020
Total number of shares and voting rights in Zealand Pharma at March 31, 2020
Copenhagen, March 31, 2020 – Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, in accordance with Section 10 of the Danish Statutory Order on Issuers' Disclosure Obligations, announces the total number of shares and voting rights in the Company at the end of a calendar month during which there have been changes to its share capital.
In Company announcements No. 05/2020 from March 20, 2020, Zealand announced an increase in share capital relating to the exercise of employee warrants, and in No. 09/2020 from March 26, 2020 and No. 11/2020 from March 31, 2020, Zealand announced an increase in share capital relating to the completion of a private placement and directed issue of new shares. Following these announcements, the table below lists the total number of shares and voting rights in Zealand up to and including March 31, 2020:
| Date | Number of shares (nominal value of DKK 1 each) | Share capital (nominal value in DKK) | Number of voting rights |
| March 31, 2020 | 36,887,952 | 36,887,952 | 36,887,952 |
For further information, please contact:
Zealand Pharma Investor Relations
+45 50 60 38 00, investors@zealandpharma.com
Lani Pollworth Morvan, Investor Relations and Communication
lpm@zealandpharma.com
About Zealand Pharma A/S
Zealand Pharma A/S (Nasdaq Copenhagen and New York: ZEAL) ("Zealand") is a biotechnology company focused on the discovery and development of innovative peptide-based medicines. More than 10 drug candidates invented by Zealand have advanced into clinical development, of which two have reached the market. Zealand’s current pipeline of internal product candidates focus on specialty gastrointestinal and metabolic diseases. Zealand’s portfolio also includes clinical license collaboration with Boehringer Ingelheim and pre-clinical license collaboration with Alexion Pharmaceuticals.
Zealand is based in Copenhagen (Søborg), Denmark. For further information about the Company's business and activities, please visit www.zealandpharma.com or follow Zealand on LinkedIn or Twitter @ZealandPharma.